Open Access

ARTICLE

A preliminary report assessing the feasibility and effectiveness of amniotic bladder therapy in patients with chronic radiation cystitis

Codrut Radoiu¹, Julian Jeberaeel¹, Raghav Madan¹, Nitin Vaishampayan^1,2, Steve Lucas^1,3, Alaa Hamada³, Nivedita Dhar^3,4

1 Wayne State University School of Medicine, Detroit, Michigan, USA
2 Karmanos Cancer Center, Detroit, Michigan, USA
3 John D. Dingell VA Medical Center, Detroit, Michigan, USA
4 Detroit Medical Center, Detroit, Michigan, USA
Address correspondence to Dr. Nivedita Dhar, John D. Dingell VA Medical Center, 4646 John R Street, Detroit, MI 48201 USA

Canadian Journal of Urology 2023, 30(4), 11607-11612.

Abstract

Introduction: Chronic radiation cystitis (CRC) can develop between 6 months and 20 years after radiation therapy that presents with symptoms of urinary frequency, urgency, bladder pain, and nocturia. Amniotic membrane (AM) is known to contain pro-regenerative properties and could thereby be a potential therapeutic modality for radiation-induced tissue injury of the bladder.
Materials and methods: CRC patients recalcitrant to previous treatments received amniotic bladder therapy (ABT) comprised of intra-detrusor injections of 100 mg micronized AM (Clarix Flo) diluted in 10 mL 0.9% preservative-free sodium chloride. Clinical evaluation and questionnaires (Interstitial Cystitis Symptom Index (ICSI), Interstitial Cystitis Problem Index (ICPI), Bladder Pain/Interstitial Cystitis Symptom Score (BPIC-SS), Overactive Bladder (OAB) Assessment Tool, and SF-12 Health Survey) were repeated at preop and 2, 4, 8 and 12 weeks post-injection.
Results: Five consecutive female patients aged 64.4 ± 20.1 years with a median CRC disease duration of 10 years were included. After ABT, BPIC-SS scores improved from baseline to 12 weeks (36.6 ± 1.1 to 12.6 ± 3.1) and this was associated with an improvement in ICSI, ICPI, OAB, and SF-12 scores. One patient had an acute urinary tract infection at 2 weeks but was successfully treated with oral antibiotics. No other adverse events related to micronized AM injections were observed. Uroflow assessments showed increases in voided volume for all five patients.
Conclusions: This data provides additional evidence for the potential benefit of ABT in patients with chronic inflammatory conditions of bladder such as CRC.

---

Keywords

---